Brainstorm Cell Therapeutics | BCLI - Operating Expenses

Stock Price
0.85
Daily Change
-0.02 -1.73%
Monthly
-5.56%
Yearly
6.92%
Q2 Forecast
0.90

Brainstorm Cell Therapeutics reported $2.24M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Brainstorm Cell Therapeutics USD 2.24M 197K Dec/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Mesoblast USD 82.31M 26.16M Dec/2025